Quarterly report pursuant to Section 13 or 15(d)

NOTES PAYABLE (Details 2)

v3.21.2
NOTES PAYABLE (Details 2)
$ / shares in Units, $ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2021
USD ($)
Equity_Instrument
Dec. 31, 2020
USD ($)
Equity_Instrument
$ / shares
Feb. 21, 2020
Debt Instrument [Line Items]      
Interest rate     10.00%
Principal Outstanding $ 22,809 $ 15,294  
Unamortized Discount 4,732 1,720  
Carrying Amount $ 18,077 $ 13,574  
Underlying Shares Notes | Equity_Instrument 10,122,974 3,946,723  
2019 Convertible Debentures [Member]      
Debt Instrument [Line Items]      
Interest rate   10.00%  
Term of Notes   18 months  
Principal Outstanding   $ 7,200  
Unamortized Discount   1,720  
Carrying Amount   $ 5,480  
Underlying Shares Notes | Equity_Instrument   3,630,000  
2019 Convertible Debentures [Member] | Minimum [Member]      
Debt Instrument [Line Items]      
Conversion price | $ / shares [1]   $ 2.00  
2019 Convertible Debentures [Member] | Maximum [Member]      
Debt Instrument [Line Items]      
Conversion price | $ / shares [1]   $ 9.52  
Convertible Debentures [Member]      
Debt Instrument [Line Items]      
Principal Outstanding   $ 7,200  
Unamortized Discount   1,720  
Carrying Amount   $ 5,480  
Underlying Shares Notes | Equity_Instrument   3,630,000  
Principal Outstanding, Current   $ 7,200  
Unamortized Discount, Current   1,720  
Convertible Debentures, Current   $ 5,480  
Underlying Shares Notes, Current | Equity_Instrument   3,630,000  
[1]

The notes are convertible into Emmaus Life Sciences, Inc. shares.